scholarly journals ADAM 12 as a second-trimester maternal serum marker in screening for Down syndrome

2007 ◽  
Vol 27 (7) ◽  
pp. 611-615 ◽  
Author(s):  
Michael Christiansen ◽  
Kevin Spencer ◽  
Jennie Laigaard ◽  
Nicholas J. Cowans ◽  
Severin Olesen Larsen ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Serum Marker ◽  
Maternal Serum ◽  
Second Trimester ◽  
Adam 12

Medically assisted reproduction and second-trimester maternal serum marker screening for Down syndrome

2003 ◽  
Vol 23 (13) ◽  
pp. 1073-1076 ◽  
Author(s):  
Françoise Muller ◽  
Sophie Dreux ◽  
Alain Lemeur ◽  
Corinne Sault ◽  
Jean Desgrès ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Assisted Reproduction ◽  
Serum Marker ◽  
Maternal Serum ◽  
Second Trimester ◽  
Medically Assisted Reproduction

ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome

2006 ◽  
Vol 26 (10) ◽  
pp. 973-979 ◽  
Author(s):  
Jennie Laigaard ◽  
Kevin Spencer ◽  
Michael Christiansen ◽  
Nicholas J. Cowans ◽  
Severin Olesen Larsen ◽  
...  
Keyword(s):  
Down Syndrome ◽  
First Trimester ◽  
Serum Marker ◽  
Maternal Serum ◽  
Adam 12

Second-trimester Down syndrome maternal serum marker screening: a prospective study of 11 040 twin pregnancies

2008 ◽  
Vol 28 (12) ◽  
pp. 1105-1109 ◽  
Author(s):  
Aurélie Garchet-Beaudron ◽  
Sophie Dreux ◽  
Nathalie Leporrier ◽  
Jean-François Oury ◽  
Françoise Muller ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Prospective Study ◽  
Serum Marker ◽  
Maternal Serum ◽  
Second Trimester ◽  
A Prospective Study ◽  
Twin Pregnancies

The proform of eosinophil major basic protein: a new maternal serum marker for Down syndrome

1999 ◽  
Vol 19 (10) ◽  
pp. 905-910 ◽  
Author(s):  
Michael Christiansen ◽  
Claus Oxvig ◽  
Jill M. Wagner ◽  
Qiu-Ping Qin ◽  
Tri H. Nguyen ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Basic Protein ◽  
Protein A ◽  
Serum Marker ◽  
Maternal Serum ◽  
Major Basic Protein ◽  
Eosinophil Major Basic Protein

scholarly journals OP25.06: Maternal serum ADAM 12 levels in Down syndrome pregnancies during the first trimester

2007 ◽  
Vol 30 (4) ◽  
pp. 543-544
Author(s):  
M. Ryynanen ◽  
Y. Valinen ◽  
J. Ignatius ◽  
P. Laitinen ◽  
T. Ahola ◽  
...  
Keyword(s):  
Down Syndrome ◽  
First Trimester ◽  
Maternal Serum ◽  
Adam 12

scholarly journals The Effect of Down Syndrome Biochemical Markers on Predicting Severity of Preeclampsia

2020 ◽  
Author(s):  
AYSE OZBAN
Keyword(s):  
Down Syndrome ◽  
Pregnant Women ◽  
Biochemical Markers ◽  
First Trimester ◽  
Maternal Serum ◽  
Screening Tests ◽  
Second Trimester ◽  
Study Results ◽  
Second Trimester Screening ◽  
Trimester Screening

Abstract Objective: This study aims to determine whether it is possible to predict preeclampsia by comparing postpartum results and test results of the pregnant women diagnosed with preeclampsia, whose first and/or second trimester screening tests were accessible, and to demonstrate the predictability of severity and week of onset.Background: 204 patients underwent renal transplantation in our center and 84 of them were female. Five of our patients (one of them had two births) gave birth to a total of 6 pregnancies.Method: 135 patients were diagnosed with preeclampsia and their first and/or second trimester screening tests were accessible, and 366 control participants gave birth to a healthy baby between 37-41 weeks after standard follow-up period for pregnancy and their screening tests were also accessible.Results: The study results show that the first trimester maternal serum PAPP-A level is significantly low in preeclamptic pregnant women, and that the second trimester maternal serum AFP and hCG levels are significantly high and uE3 levels are significantly low The results also suggest that the first and second trimester Down syndrome biochemical markers can be used in preeclampsia screening.Conclusion: Among these markers, uE3 is the parameter which affects the possibility of preeclampsia the most. However, the first and second trimester Down syndrome biochemical markers are not effective in predicting the severity and onset week of preeclampsia.

Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity

2003 ◽  
Vol 23 (4) ◽  
pp. 331-335 ◽  
Author(s):  
Fran�oise Muller ◽  
Sophie Dreux ◽  
Henry Dupoizat ◽  
Serge Uzan ◽  
Marie-Fran�oise Dubin ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Maternal Serum ◽  
Second Trimester ◽  
Maternal Serum Screening ◽  
Serum Screening ◽  
Twin Pregnancies

scholarly journals Maternal Serum Invasive Trophoblast Antigen (Hyperglycosylated hCG) as a Screening Marker for Down Syndrome during the Second Trimester

2004 ◽  
Vol 50 (10) ◽  
pp. 1804-1808 ◽  
Author(s):  
Glenn E Palomaki ◽  
Louis M Neveux ◽  
George J Knight ◽  
James E Haddow ◽  
Raj Pandian
Keyword(s):  
United States ◽  
Down Syndrome ◽  
False Positive Rate ◽  
The United States ◽  
Maternal Serum ◽  
Second Trimester ◽  
Marker Panel ◽  
Screening Performance ◽  
Β Hcg ◽  
Screening Marker

Abstract Background: Approximately two million pregnancies in the United States are screened for Down syndrome annually by use of second-trimester maternal serum markers. At present, a combination of four markers can identify 75% of affected pregnancies when 5% of screened women are classified as candidates for amniocentesis. Although not currently included in screening panels, invasive trophoblast antigen (ITA) is a promising screening marker in serum or urine in both the second and first trimesters. This study aims at better defining the screening performance of serum ITA in the second trimester. Methods: In an earlier study, serum samples from an unbiased sampling of 45 Down syndrome (cases) and 238 unaffected (control) pregnancies between 14 and 20 weeks of gestation were collected from various centers in the United States. Samples were aliquoted and stored at −20 °C for 8 years. We measured ITA in these samples and determined the screening performance both univariately and in combination with other screening markers. Results: The median ITA in Down syndrome pregnancies was >3.00 multiples of the median, higher than that found for human chorionic gonadotropin (hCG) or free β-hCG. At a 5% false-positive rate, ITA univariately detected 38% and 40% of Down syndrome pregnancies, respectively, when assigned by date of last menstrual period or ultrasound date. Modeling yielded rates of 45% and 48%. ITA correlated strongly with hCG and free β-hCG. When substituted for either of these in a multiple marker panel, ITA performed comparably. Conclusions: This study indicates that serum ITA is an effective marker for Down syndrome. It is highly correlated with both hCG and free β-hCG and could replace either of them in a multiple marker panel.

Sign in / Sign up

Export Citation Format

Share Document